BeyondSpring Inc.
BYSI Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
Last close · Oct 23, 2026
$0.43
3.1%What BeyondSpring Inc. does
No business description yet.
- Legal name
- BeyondSpring Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Accession · CIK
- 0001171843-26-001908
0001677940
Revenue and margins
BeyondSpring Inc. had $0.0M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$19.8M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
BeyondSpring Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably BeyondSpring Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $5.4M | $2.9M | $12.6M |
| Current ratio | 2.3x | 2.6x | 1.5x |
| Quick ratio | 2.3x | 2.6x | 1.5x |
| Total assets | $24.8M | $34.3M | $25.9M |
| Total liabilities | $48.3M | $48.6M | $49.9M |
| Shareholders' equity | −$26.8M | −$32.9M | −$32.2M |
| Net debt (− = net cash) | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✕ |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | ✕ | ✕ |
| F-score | — / 3 | — / 6 | — / 6 |
| Accruals ratio | −18.3% | 18.0% | 62.3% |
| Altman Z'' | −53.98 | −37.77 | −52.49 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $0.0M | $0.0M | $0.0M |
| Research and development | $7.3M | $2.6M | $4.4M |
| Operating income | −$15.1M | −$8.8M | −$8.9M |
| Pretax income | −$13.9M | −$8.8M | −$8.6M |
| Income tax | −$0.1M | $0.1M | $0.1M |
| Net income | −$21.0M | −$11.1M | −$1.0M |
| Cash flow | |||
| Cash from operations | −$16.5M | −$16.4M | −$19.8M |
| Capital expenditure | $0.1M | $0.2M | $0.1M |
| Free cash flow | −$16.6M | −$16.7M | −$19.8M |
| Depreciation and amortization | $0.3M | $0.3M | $0.1M |
| Stock-based compensation | $0.8M | $2.3M | $0.7M |
| Balance sheet | |||
| Cash and short-term investments | $5.4M | $2.9M | $12.6M |
| Current assets | $18.4M | $28.6M | $20.9M |
| Current liabilities | $8.0M | $11.0M | $13.6M |
| Property and equipment, net | $0.3M | $0.2M | $0.2M |
| Total assets | $24.8M | $34.3M | $25.9M |
| Total liabilities | $48.3M | $48.6M | $49.9M |
| Shareholders' equity | −$26.8M | −$32.9M | −$32.2M |
| Returns | |||
| Return on capital employed | −89.5% | −37.6% | −72.4% |
| Return on assets | −84.8% | −37.6% | −3.3% |
| Financial health | |||
| Current ratio | 2.3x | 2.6x | 1.5x |
| Quick ratio | 2.3x | 2.6x | 1.5x |
| Quality scores | |||
| Altman Z'' | −54.0 | −37.8 | −52.5 |
| Accruals ratio | −18.3% | 18.0% | 62.3% |
Source: SEC EDGAR XBRL filings (CIK 0001677940). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.